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Abstract
Background
Despite improvements in treatment for rheumatoid arthritis (RA), psoriatic arthritis (PsA)
and spondyloarthritis (axSpA), several key unmet needs remain, such as fatigue. The objec-
tive of this study was to describe the severity of fatigue, disease characteristics and socio-
economic factors in people with RA, PsA and axSpA.
Methods
The study was designed as a cross-sectional survey collecting patient characteristics such
as disease characteristics, socioeconomic factors and fatigue in people with RA, PsA and
axSpA in Denmark. Respondents were consecutively recruited for the study over a six-
month period in 2018 via routine visits to outpatient rheumatology clinics. Study nurses col-
lected information on diagnosis, current disease-related treatment and disease activity from
medical journals. People were invited to complete a questionnaire related to socioeconomic
factors and containing the FACIT-Fatigue subscale. Descriptive statistics were analyzed
using SAS.
Results
We invited 633 people to participate, and 488 (77%) completed the questionnaire. Women
constituted 62% of respondents, and the mean age was 53.5 years. Respondents had on
average been diagnosed between 11 and 15 years ago. Overall, 79% had no changes to
their disease-related treatment during the past year, and the average disease activity as
indicated by DAS28 for RA and PsA was 2.48 and 2.36, respectively, and BASDAI for
axSpA was 28.40. Fatigue was present in all three diagnoses (mean: 34.31). The mean
fatigue score varied from respondents answering that they suffered from no or little fatigue
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(mean: 45.48) to extreme fatigue (mean: 10.11). Analyses demonstrated that the respon-
dents were not considerably different from nonrespondents, and the study population is con-
sidered representative compared with Danish RA and axSpA patients in the Danish
National Rheumatology Registry, the DANBIO database.
Conclusion
We found that the majority of the study population were fatigued (61%). They had low dis-
ease activity and few disease-related treatment changes.
Introduction
Fatigue is described as extreme tiredness, typically resulting from mental or physical exertion
or illness [1]. However, an internationally accepted definition of fatigue does not exist [2]. One
of the most commonly known illnesses to cause fatigue is inflammatory arthritis, and several
studies have demonstrated that fatigue is a prevalent symptom in people with rheumatoid
arthritis (RA), psoriatic arthritis (PsA) and spondyloarthritis (axSpA) [3–12]. Clinically impor-
tant levels of fatigue are reported in 42% of the patients [13], while prevalence rates of 80% or
more have also been reported in adults with RA [14–17], and it is perceived as a dominating
problem with a greater impact on everyday life than pain [18].
In recent years, there has been an increased focus on fatigue and how fatigue correlates
with other symptoms or conditions. According to a recent review of fatigue and RA, severe
fatigue is common among individuals with RA and has a significant impact on quality of life
[3]. In addition, RA-related factors (e.g., inflammation, pain) are associated with greater
fatigue, but other factors, such as physical inactivity, sleep disturbance and depression, explain
the major differences in fatigue [3]. Despite this recent increased focus on fatigue in arthritis,
there is still a lack of research analyzing the severity of fatigue across diagnoses in inflamma-
tory arthritis such as PsA and axSpA. Further, there is a lack of studies analyzing a potential
correlation between fatigue and disease-specific characteristics and socioeconomic factors [3–
12].
The prevalence of RA, PsA and axSpA varies globally. In Europe, the estimated prevalence
is between 0.3% and 1% for RA [19], 0.001% and 0.42% for PsA [20], and 0.2% and 1.61% for
axSpA [21]. Still, RA, PsA and axSpA are the most common types of inflammatory arthritis in
the outpatient rheumatology clinics in Denmark. The estimated prevalence in the Danish pop-
ulation is 0.7% for RA [22], 0.1%-0.2% for PsA [23] and 0.3% for axSpA [24].
The objective of this study was to describe the severity of fatigue, disease characteristics and
socioeconomic factors in people with RA, PsA and axSpA.
Materials and methods
Study population
This study was designed as a cross-sectional study of people with RA, PsA and axSpA currently
enrolled at one of Rigshospitalet’s two outpatient clinics in Glostrup and Frederiksberg, Den-
mark. We aimed to recruit a representative sample of people with RA, PsA and axSpA,
amounting to 527 (11% of patients with RA, PsA and axSpA enrolled in one of the two outpa-
tient clinics). Inclusion criteria were people 18 and older with a confirmed diagnosis of RA,
PsA or axSpA; who had been enrolled at one of the two clinics for more than four weeks; who
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were able to read, understand and write Danish; and who signed an informed consent to par-
ticipate in the study. People were consecutively recruited between January and June 2018.
Characteristics of respondents from medical journals
We developed a questionnaire, which was used by the study nurse to collect informed consent
and characteristics from each respondent’s medical journal (S1 and S2 Files). Characteristics
such as type of arthritis, age, gender, treatment (disease-modifying antirheumatic drug
(DMARD) or biologic), treatment changes and disease activity score (Disease Activity Score-
28 (DAS28), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and/or Bath
Ankylosing Spondylitis Functional Index (BASFI)) were obtained. For respondents eligible to
participate, but not wishing to do so, information on diagnosis (RA, PsA, axSpA), gender, year
of birth and reason for not wanting to participate in the study was collected if the respondent
gave permission. This information was used for the dropout analysis.
Patient-reported outcomes
We developed a patient questionnaire, which was used to collect patient demographics (S3 and
S4 Files). It included outcomes such as years since diagnosis, marital status, education,
employment status and household income. The questionnaire also included several other
patient-reported outcomes (PROs), of which only the results of fatigue are reported in this
study. The other results will be reported elsewhere. We used two scales to measure fatigue: the
single visual analog scale (VAS) item from the Health Assessment Questionnaire (HAQ) [25]
and the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale [26], both
validated to measure fatigue in patients with chronic illnesses, among others, in RA and PsA
populations [10,27]. In the HAQ, people were asked: “How tired are you?” The scale ranges
from 0 to 100, where 0 represents no fatigue and 100 represents severe fatigue. The FACIT-Fa-
tigue scale is a 13-item questionnaire assessing self-reported fatigue. Originally developed as
an addition to the Functional Assessment of Cancer Therapy measurement system, the
FACIT-Fatigue scale developers have demonstrated that the fatigue subscale can stand alone
as a brief, reliable and valid measuring tool. Items in the FACIT-Fatigue scale are scored 0–4
(five answer categories), and the total FACIT-Fatigue score ranges from 0 to 52 [28]. Based on
this and to enable an analysis of severity of fatigue, we divided the responses into four grades
of severity: respondents with no or little fatigue (composite score between 40 and 52), some
fatigue (composite score between 27 and 39), quite a lot of fatigue (composite score between
14 and 26) and extreme fatigue (composite score between 0 and 13). If respondents scored 39
or lower on the FACIT-Fatigue scale, we categorized the respondents as suffering from fatigue.
Thus, higher scores on the FACIT-Fatigue scale indicate less fatigue, while the opposite is true
for the VAS where lower scores indicate less fatigue.
Other measurements
This study is a part of a larger study “The impact of fatigue in patients with rheumatoid arthri-
tis, psoriatic arthritis and spondyloarthritis in Denmark”. Besides the abovementioned, data
on work productivity, health related quality of life, sleep and depression were collected, and
will be reported elsewhere (in preparation).
Data collection
The questionnaires were pilot-tested among five people with RA (not included in the analysis).
The pilot was conducted in the same setting as the study cohort on a random day with people
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with RA, PsA and axSpA visiting the clinics for routine visits. The questionnaire was tested for
comprehensibility, user friendliness and time consumption. As the primary part of the ques-
tionnaire was made up of validated scales, we did not test the comprehensibility of the specific
scales but of the entire questionnaire, as well as the flow in the questionnaire. In general, the
pilots answered within an expected time frame and found the questionnaire acceptable and
understandable.
People with RA, PsA or axSpA were approached by a study nurse in each clinic and enrolled
in the study based on informed consent. The study nurse collected characteristics via a medical
journal while the person completed a self-reported questionnaire on an iPad. If the respondent
preferred to complete the questionnaire at home, the respondent was either given a link to the
online questionnaire or a paper version of the questionnaire and a stamped, addressed enve-
lope and was asked to return the questionnaire by ordinary mail. Study participation was
encouraged by the study nurse for those people who agreed to participate in the survey but for
some reason did not answer the questionnaire. The study was conducted with approval from
the Danish Data Protection Agency (j.nr. 2012-41-1199) and approval from the Ethics Com-
mittee of the Capital Region of Denmark (Protocol 17021125). The Danish Medicines Agency
was informed about the execution of the study, as per current Danish guidelines (case no.
2017071026).
Database and statistical analysis
The questionnaires were both set up in SurveyXact, an online questionnaire collection pro-
gram developed by Rambøll. The answers of those respondents choosing to complete the ques-
tionnaire on paper were entered manually into SurveyXact. Statistical analyses were conducted
in SAS and Microsoft Excel. Where applicable, we applied analysis of variance and Pearson’s
chi-square test to test for significant differences between groups.
Results
We invited 633 people to complete the questionnaire, and of those, 488 completed it (77%
response rate). Of the 145 (23%) who did not complete the questionnaire, 18 (3%) refused to
participate, 117 (18%) agreed but never started the questionnaire, and 10 (2%) partly com-
pleted the questionnaire (Fig 1).
Study population
In total, 488 respondents completed the questionnaire (450 electronically and 38 on paper). Of
the 488, 60% had a diagnosis of RA, 17% a diagnosis of PsA and 23% a diagnosis of axSpA
Fig 1. Flow chart.
https://doi.org/10.1371/journal.pone.0218831.g001
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(Table 1). Of all respondents, 62% were women; however, the distribution across the three
diagnoses was uneven, with 79% of the RA respondents being women while 46% and 30% of
the PsA and axSpA respondents were women, respectively. The youngest population was
found among the axSpA respondents (mean age: 43.6), with 35% of the axSpA respondents
being between 18 and 39 years of age, compared with 13% and 16% for RA and PsA, respec-
tively. The oldest population was found among the RA respondents (mean age: 57.4), with
49% of RA respondents being above 60 years of age. The majority of the respondents did not
change treatment within the past 12 months (79%), a number that is very consistent across the
three diagnoses (RA: 81%; PsA: 79%; axSpA: 73%). The current treatment varied across diag-
noses, but on average, 39% were receiving biosimilar DMARD (bsDMARD), 18% conven-
tional synthetic DMARD (csDMARD) and 42% both (1% no current treatment). The average
disease activity as indicated by DAS28 for RA and PsA was 2.48 (standard deviation (SD):
1.11) and 2.36 (SD: 0.99), respectively, and BASDAI for axSpA was 28.40 (SD: 23.78). BASFI
was 30.93 (SD: 22.93) for PsA and 27.65 (SD: 23.93) for axSpA.
Patient-reported socioeconomic characteristics
Among the newly diagnosed (0–5 years), the highest share of respondents was among those
with axSpA (30%) (Table 2). More than half of the respondents (64%) were married/living
together with a partner (with or without children) and there was little variation between the
diagnoses. Almost half of the respondents (46%) had a bachelor’s degree or higher, and the
majority of the population belonged to the active workforce (58%). Finally, more than half had
a household income above 400,000 DKK.
Table 1. Characteristics from medical journals.
All RA PsA axSpA
N (%) n (%) n (%) n (%)
All 488 (100%) 293 (60%) 85 (17%) 110 (23%)
Sex
Male 185 (38%) 62 (21%) 46 (54%) 77 (70%)
Female 303 (62%) 231 (79%) 39 (46%) 33 (30%)
Age
18–39 years 91 (19%) 38 (13%) 14 (16%) 39 (35%)
40–59 years 221 (45%) 111 (38%) 46 (54%) 64 (58%)
60+ years 176 (36%) 144 (49%) 25 (29%) 7 (6%)
Age in years, mean (SD) 53.5 (14.5) 57.4 (14) 52.6 (13.2) 43.6 (11.9)
Treatment change in the past 12 months
0 385 (79%) 238 (81%) 67 (79%) 80 (73%)
1 92 (19%) 46 (16%) 17 (20%) 29 (26%)
2 or more 11 (2%) 9 (3%) 1 (1%) 1 (1%)
Current treatment
bsDMARD 191 (39%) 69 (24%) 33 (39%) 89 (81%)
csDMARD 90 (18%) 68 (23%) 22 (26%) 0 (0%)
bsDMARD and csDMARD 204 (42%) 155 (53%) 29 (34%) 20 (18%)
No current treatment 3 (1%) 1 (0%) 1 (1%) 1 (1%)
Disease activity status
DAS28, mean (SD) 2.45 (1.08) 2.48 (1.11) 2.36 (0.99) 2.35 (0.9)
BASDAI, mean (SD) 30.59 (23.56) NA 33.54 (23.07) 28.40 (23.78)
BASFI, mean (SD) 29.05 (23.51) NA 30.93 (22.93) 27.65 (23.93)
The sum of percentages does not reach 100% due to rounding errors.
https://doi.org/10.1371/journal.pone.0218831.t001
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Nonrespondents
When analyzing the nonrespondents according to characteristics, it became evident that non-
respondents were distributed evenly across the diagnoses compared with respondents
(Table 3). However, there were significantly more men in the nonrespondent group (50%)
than the respondent group (38%) (p = 0.0075). The average age of the nonrespondents was 50
years vs. 53 in the respondent group (p = 0.0489). The percentage of nonrespondents was
higher in the youngest age group (18–39) than in the respondent group (28% vs. 19%), and,
finally, there was no difference with regard to treatment changes.
Representativity
In Denmark, data on people with RA and axSpA currently receiving DMARDs is routinely col-
lected at scheduled visits to rheumatology centers in the Danish National Rheumatology Regis-
try, the DANBIO database. However, the DANBIO database do not include information on
people with PsA. The data collected includes age and gender, type of treatment, and treatment
Table 2. Socioeconomic characteristics (patient-reported).
All RA PsA axSpA
N (%) n (%) n (%) n (%)
All 488 (100%) 293 (60%) 85 (17%) 110 (23%)
Years since diagnosis
0–5 years 105 (22%) 57 (19%) 15 (18%) 33 (30%)
6–10 years 105 (22%) 62 (21%) 24 (28%) 19 (17%)
11–15 years 110 (23%) 71 (24%) 17 (20%) 22 (20%)
16–20 years 70 (14%) 39 (13%) 14 (16%) 17 (15%)
More than 20 years 98 (20%) 64 (22%) 15 (18%) 19 (17%)
Type of household
Married/living togethera 312 (64%) 185 (63%) 56 (66%) 71 (65%)
Singleb 162 (33%) 103 (35%) 25 (29%) 34 (31%)
Living at home with parents or house
sharing with other adults
13 (3%) 4 (1%) 4 (5%) 5 (5%)
Highest obtained education
Elementary school or high school 99 (20%) 58 (20%) 20 (24%) 22 (20%)
Secondary or short-cycle tertiary 166 (34%) 94 (32%) 33 (39%) 39 (35%)
Bachelor’s or higher 222 (46%) 141 (48%) 32 (38%) 49 (45%)
Employment status
Employedc 281 (58%) 148 (51%) 48 (57%) 85 (77%)
Unemployed 19 (4%) 8 (3%) 7 (8%) 4 (4%)
Retiredd 123 (25%) 100 (34%) 17 (20%) 6 (5%)
Homemaker, student or other 62 (13%) 35 (12%) 12 (14%) 15 (14%)
Total household income
Below 400,000 DKK 183 (38%) 112 (39%) 28 (33%) 43 (39%)
400,000 DKK or more 250 (52%) 140 (48%) 48 (56%) 62 (56%)
Refused to answer 51 (11%) 37 (13%) 9 (11%) 5 (5%)
The sum of percentages does not reach 100% due to rounding errors. Some socioeconomic information was not available for all respondents.
aMarried/living together with or without children.
bSingle with or without children.
cEmployed full time, part time or flexible hours.
dAge-related retirement or health-related early retirement because of arthritis or other reason.
https://doi.org/10.1371/journal.pone.0218831.t002
Severity of fatigue in people with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis
PLOS ONE | https://doi.org/10.1371/journal.pone.0218831 June 28, 2019 6 / 13
changes registered by the nurse or physician as well as patient-reported data (HAQ scale)
[25,29]. This data allows us to analyze whether the study cohort is representative of both the
Glostrup/Frederiksberg cohort and the full Danish RA and axSpA population.
In 2017, there were 4,788 people with RA, PsA and axSpA enrolled at the Glostrup and
Frederiksberg outpatient rheumatology clinics [30]. We targeted 527 people with RA, PsA and
axSpA, and of those, 488 (93% of target) completed the questionnaire, with 96% of RA, 83% of
PsA and 91% of axSpA participating in the study (Table 4).
When comparing the study cohort with the Glostrup and Frederiksberg cohort from DAN-
BIO 2017, the RA respondents are slightly younger than the average Glostrup and Frederiks-
berg cohort from 2017 (56/60 vs. 61/60 for RA and 45/42 vs. 45/41 for axSpA, respectively)
(Table 5). Further, there are slightly more RA women in the study cohort than in the cohort
from Glostrup and Frederiksberg (78%/80% vs. 77%/76%) and slightly fewer axSpA women in
the study cohort than in the cohort from Glostrup and Frederiksberg (29%/31% vs. 35%/34%)
[31]. When comparing the study cohort with the full Danish RA and axSpA population from
DANBIO 2017, the RA and axSpA respondents are slightly younger than the DANBIO cohort
Table 3. Analysis of nonrespondents.
Nonrespondents Study population P-value chi-square test
n (%) n (%)
All 145 (100%) 488 (100%)
Diagnosis 0.3446
RA 79 (54%) 293 (60%)
PsA 25 (17%) 85 (17%)
axSpA 41 (28%) 110 (23%)
Sex 0.0075
Male 73 (50%) 185 (38%)
Female 72 (50%) 303 (62%)
Age 0.0489
18–39 years 40 (28%) 91 (19%)
40–59 years 63 (43%) 221 (45%)
60+ years 42 (29%) 176 (36%)
Mean age 50 53
Treatment change in the past 12 monthsa 0.3861
0 93 (73%) 385 (79%)
1 30 (24%) 92 (19%)
2 or more 4 (3%) 11 (2%)
aOut of 145 nonrespondents, 18 did not register a treatment change within the past 12 months (n = 127).
https://doi.org/10.1371/journal.pone.0218831.t003
Table 4. Respondents.
RA PsA axSpA Total
Number of people enrolled, in total 2,764 924 1,100 4,788
Glostrup 1,600 557 656 2,813
Frederiksberg 1,164 367 444 1,975
Target 304 102 121 527
Invited/eligible people NA NA NA 633
Respondents 293 85 110 488
Percentage of target 96% 83% 91% 93%
https://doi.org/10.1371/journal.pone.0218831.t004
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average (57 vs. 63 for RA and 44 vs. 45 for axSpA, respectively). Further, there are more RA
women and fewer axSpA women in the study cohort than in the DANBIO cohort (79% vs.
71% for RA and 30% vs. 40% for axSpA, respectively) [31].
Fatigue
The mean fatigue scores on the VAS were 42.16 (SD: 29.95), 49.69 (SD: 29.18) and 45.01 (SD:
29.57) for RA, PsA and axSpA, respectively. The mean VAS fatigue scores did not vary statisti-
cally significantly among the three diagnoses (p = 0.11). On the FACIT-Fatigue scale, the
mean fatigue score was 34.31 (SD: 6.08), and fatigue was present in all three diagnoses
(Table 6). The mean fatigue scores across diagnoses was not significant (p = 0.078). The mean
fatigue score was 34.86 (SD: 11.04) among RA respondents, 31.83 (SD: 10.89) among PsA
respondents and 34.77 (SD: 11.44) among axSpA respondents. The mean fatigue score varied
among respondents, indicating that they suffered from no or a little fatigue (mean: 45.48; SD:
3.62) to extreme fatigue (mean: 10.11; SD: 3.61). In total, 61% of the respondents expressed
fatigue (some, quite a lot or extreme).
Discussion
In this study, 488 respondents (77% response rate) completed the questionnaire, and fatigue
was frequent in all three diagnoses (RA, PsA and axSpA). Women constituted 62% of respon-
dents, and the mean age was 53.5 years, which is in accordance with other studies that have
found that more fatigue has been reported in association with advancing age [32,33] and
female sex [32–35]. We also found that the study population had low disease activity and was
Table 5. Representability compared with DANBIO data.
Study population
(Glostrup)
Study population
(Frederiksberg)
Study population
(all)
DANBIO
(Glostrup)
DANBIO
(Frederiksberg)
DANBIO
(all Denmark)
RA axSpA RA axSpA RA axSpA RA axSpA RA axSpA RA axSpA
Women (%) 78% 29% 80% 31% 79% 30% 77% 35% 76% 34% 71% 40%
Mean age 56 45 60 42 57 44 61 45 60 41 63 45
https://doi.org/10.1371/journal.pone.0218831.t005
Table 6. Fatigue measured by FACIT-Fatigue score.
Mean (SD)
All RA PsA axSpA
N (%) n (%) n (%) n (%)
Number 487 (100%) 292 (100%) 85 (100%) 110 (100%)
Mean fatigue (SD) 34.31 (6.08) 34.86 (11.04) 31.83 (10.89) 34.77 (11.44)
Severity of fatigue
No or little fatiguea 45.48 (3.62) 189 (39%) 120 (41%) 23 (27%) 46 (42%)
Some fatigueb 33.05 (3.69) 171 (35%) 99 (34%) 39 (46%) 33 (30%)
Quite a lot of fatiguec 20.91 (3.57) 109 (22%) 62 (21%) 19 (22%) 28 (25%)
Extreme fatigued 10.11 (3.61) 18 (4%) 11 (4%) 4 (5%) 3 (3%)
Higher fatigue scores indicate less fatigue.
aFACIT-Fatigue score: 40–52.
bFACIT-Fatigue score: 27–39.
cFACIT-Fatigue score: 14–26.
dFACIT-Fatigue score: 0–13.
https://doi.org/10.1371/journal.pone.0218831.t006
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relatively stable, with 79% reporting no changes to their disease-related treatment during the
past year.
Despite this, the study population suffered from fatigue. We measured fatigue in two ways.
On the VAS, we found a mean fatigue score of 42.16 (SD: 29.95), 49.69 (SD: 29.18) and 45.01
(SD: 29.57) for RA, PsA and axSpA, respectively. Our findings are consistent with mean fatigue
scores previously documented in a cross-sectional Norwegian study (mean fatigue score on
the VAS: 39.9, 43.6 and 43.6 for RA, PsA and axSpA, respectively) [36]. We also used the
FACIT-Fatigue instrument to evaluate fatigue. Fatigue was present in all three diagnoses, with
a mean FACIT-Fatigue score of 34.31 (SD: 6.08) across diagnoses, which was lower than previ-
ously reported among a large representative sample (N = 2,426) of the average German popu-
lation (mean: 43.5; SD: 8.3) [37] and a large sample (N = 1,010) of the general U.S. population
(mean: 43.6; SD: 9.4) [38]. Among the studies we identified measuring fatigue by the FACIT--
Fatigue score in people with RA, the score ranged from 34.6 to 42 [39–41] (the fatigue score of
42 was found among RA patients with low disease activity), which is somewhat higher than the
mean fatigue score identified in the current study (mean: 34.86; SD 11.04). The mean FACIT--
Fatigue score among PsA patients was slightly lower (mean: 31.83; SD: 10.89) than previously
reported in a study of Canadian people with PsA (mean: 35.8) [10]. To date, no studies have,
to our knowledge, measured fatigue by the FACIT-Fatigue score among axSpA patients. In
total, 61% (RA: 59%; PsA: 73; axSpA: 58%) of the respondents expressed that fatigue was a
symptom they were affected by to some extent. This is in line with the prevalence of fatigue
previously reported among patients with RA, found to vary from 40% to 80% [3,42,43], and
the prevalence among PsA patients, found to vary from 44.7% to 78.2% [11,12]. The prevalence
of fatigue by FACIT-Fatigue score among axSpA patients has not been estimated in any previ-
ous research.
The study population from both disease-specific and socioeconomic perspectives was a
well-functioning group of people. Also, overall, the population belonged to the active work-
force (58%). This is noteworthy because a recently published study that aimed to determine
factors associated with work productivity found a strong association of fatigue with all work
measures as well as with daily activity impairment [44]. This emphasizes the need for focusing
on increased knowledge about and focus on how to reduce fatigue, which may help optimize
work status in people with inflammatory arthritis.
To date, the FACIT-Fatigue scale has been used to measure progress in fatigue in both
cross-sectional and longitudinal studies. These studies have reported a minimal important dif-
ference of 3–8.3 on the FACIT-Fatigue scale from 0 to 52 [45].
Strengths and limitations
Our study has several strengths. One of the main strengths of the study is the data source for
the patient characteristics, which were recorded by trained study nurses from the respondents’
medical journals. This method excludes potential recall biases seen in surveys exclusively
based on patient-reported data. Another strength of the study is the recruitment method,
which has ensured a high response rate. Similarly, the dropout analysis showed that the
respondents were not considerably different from the nonrespondents. Finally, our study is
considered representative of the Danish RA, PsA and axSpA populations.
We acknowledge, however, that the study has some limitations. The study is cross-sectional
and can therefore not provide any conclusions concerning causality. It can generate only
hypotheses, which can be further analyzed in future prospectively conducted studies. Despite a
good representation in the study cohort of both genders and age groups, the study cohort is
slightly older and consists of more women than the group of nonrespondents. The same
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tendency is seen in other surveys [46]. The study is further limited by its geographical scope,
which is limited to two clinics in the Capital Region of Denmark. The study cohort is slightly
younger than the average Danish DANBIO population, and there were slightly more RA
women and fewer axSpA respondents in the study cohort. But as the data collection method
did not differ from that of DANBIO, we assume that the explanation is due to chance, as the
data collection period did not last a full year but covered only six months.
Scales differ in their focus, some measuring severity only and others duration and impact
on a range of functions as well as different aspects of fatigue. In this study, we focused on mea-
suring the severity of fatigue using both VAS and FACIT-Fatigue scores, which measured one
aspect of fatigue (unidimensional) and not the multidimensional aspects of fatigue, which can
be viewed as a limitation.
Conclusion
We found that the majority of the study population was fatigued. The study cohort represents
a stable group with low disease activity, few disease-related treatment changes and strong
attachment to the labor market. The study cohort is considered representative, and the results
warrant further analyses of how fatigue correlates with other PROs and how it differs across
the diagnoses.
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